Sun Pharma unit inks licensing pact with US-based firm to introduce drug to treat stroke

"The Phase 3 clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke," Sun Pharma India Business CEO Kirti Ganorkar said. Tyvalzi is a first-in-class innovative drug which can help improve the quality of life of stroke patients, he added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9k8dEKG
via IFTTT